Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription 03.06.2024 1 BMC Cancer 2 Br J Radiol 1 Cancer 1 Eur Radiol 3 Eur Urol 1 J Nucl Med 1 JAMA 1 Nat Rev Urol 1 PLoS One 4 Prostate 1 Urol Int

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. WANG B, Pan J, Zhang T, Ni X, et al
   Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen
   BMC Cancer. 2024;24:643.
   PubMed         Abstract available
   
   

   
   Br J Radiol

2. STARKE A, Poxon J, Patel K, Wells P, et al
   Clinical evaluation of the efficacy of limbus artificial intelligence software to augment contouring for prostate and nodes radiotherapy.
   Br J Radiol. 2024;97:1125-1131.
   PubMed         Abstract available
   
   
3. IN DE BRAEKT T, van Rooij SBT, Daniels-Gooszen AW, Scheepens WA, et al
   Accuracy of Magnetic Resonance Imaging-Ultrasound Fusion-Guided and Systematic Biopsy of the Prostate.
   Br J Radiol. 2024 Apr 16:tqae080. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Cancer

4. TINSLEY SA, Finati M, Stephens A, Chiarelli G, et al
   Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.
   Cancer. 2024 May 28. doi: 10.1002/cncr.35386.
   PubMed         Abstract available
   
   

   
   Eur Radiol

5. NAKAI H, Takahashi H, Adamo DA, LeGout JD, et al
   Decreased prostate MRI cancer detection rate due to moderate to severe susceptibility artifacts from hip prosthesis.
   Eur Radiol. 2024;34:3387-3399.
   PubMed         Abstract available
   
   

   
   Eur Urol

6. VICKERS AJ
   Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
   Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024.
   PubMed        
   
   
7. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
   Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer L
   Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024.
   PubMed        
   
   
8. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
   Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In
   Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024.
   PubMed        
   
   

   
   J Nucl Med

9. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
   Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
   J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
   PubMed         Abstract available
   
   

   
   JAMA

10. NEWCOMB LF, Schenk JM, Zheng Y, Liu M, et al
    Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
    JAMA. 2024 May 30. doi: 10.1001/jama.2024.6695.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

11. GALEY L, Olanrewaju A, Nabi H, Paquette JS, et al
    Rediscovering citrate as a biomarker for prostate cancer.
    Nat Rev Urol. 2024 May 29. doi: 10.1038/s41585-024-00899.
    PubMed        
    
    

    
    PLoS One

12. PARKER LA, Caballero-Romeu JP, Chilet-Rosell E, Hernandez-Aguado I, et al
    Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study).
    PLoS One. 2024;19:e0303203.
    PubMed         Abstract available
    
    

    
    Prostate

13. FERRO M, Crocetto F, La Civita E, Fiorenza M, et al
    Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
    Prostate. 2024 May 26. doi: 10.1002/pros.24752.
    PubMed         Abstract available
    
    
14. TIRUYE T, Roder D, FitzGerald LM, O'Callaghan M, et al
    Impact of comorbidities on prostate cancer-specific mortality: A population-based cohort study.
    Prostate. 2024 May 26. doi: 10.1002/pros.24750.
    PubMed         Abstract available
    
    
15. TOUMA N, Larose M, Ouellet J, Bedard-Tremblay D, et al
    External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high-grade prostate cancer patients.
    Prostate. 2024 May 27. doi: 10.1002/pros.24742.
    PubMed         Abstract available
    
    
16. WENZEL M, Hoeh B, Hurst F, Koll F, et al
    Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
    Prostate. 2024 May 29. doi: 10.1002/pros.24754.
    PubMed         Abstract available
    
    

    
    Urol Int

17. GLOGER S, Paulics L, Philippou C, Philippou S, et al
    Perioperative rates of incidental prostate cancer after aquablation and holmium laser enucleation of the prostate (HoLEP).
    Urol Int. 2024 May 27. doi: 10.1159/000539014.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.